Acinetobacter baumannii is a bacterial pathogen with increasing impact in healthcare settings, due in part to this organism’s resistance to many antimicrobial agents, with pneumonia and bacteremia as the most common manifestations of disease. A significant proportion of clinically-relevant A. baumannii strains are resistant to killing by normal human serum (NHS), an observation supported here by showing that 12 out of 15 genetically diverse strains of A. baumannii are resistant to NHS killing. To expand our understanding of the genetic basis of A. baumannii serum resistance, a transposon-sequencing (Tn-seq) approach was used to identify genes contributing to this trait. An ordered Tn-library in strain AB5075 with insertions in every non-essential gene was subjected to selection in NHS. We identified 50 genes essential for the survival of A. baumannii in NHS, including already known serum resistance factors, and many novel genes not previously associated with serum resistance. This latter group included the maintenance of lipid asymmetry (mla) genetic pathway as a key determinant in protecting A. baumannii from the bactericidal activity of NHS via the alternative complement pathway. Follow up studies validated the role of 8 additional genes identified by Tn-seq in A. baumannii resistance to killing by NHS but not by normal mouse serum, highlighting the human-species specificity of A. baumannii serum resistance. The identification of a large number of genes essential for serum resistance in A. baumannii indicates the degree of complexity needed for this phenotype, which might reflect a general pattern pathogens rely on to cause serious infections.
Acinetobacter baumannii is a notorious pathogen that has emerged as a healthcare nightmare in recent years because it causes serious infections that are associated with high morbidity and mortality rates. Due to its exceptional ability to acquire resistance to almost all available antibiotics, A. baumannii is currently ranked as the first pathogen on the World Health Organization’s priority list for the development of new antibiotics. The versatile range of effectors secreted by A. baumannii represents a large proportion of the virulence arsenal identified in this bacterium to date. Thus, these factors, together with the secretory machinery responsible for their extrusion into the extracellular milieu, are key targets for novel therapeutics that are greatly needed to combat this deadly pathogen. In this review, we provide a comprehensive, up-to-date overview of the organization and regulatory aspects of the Acinetobacter secretion systems, with a special emphasis on their versatile substrates that could be targeted to fight the deadly infections caused by this elusive pathogen.
Exploring
the structure–activity relationship (SAR) at the
cationic part of arylthiazole antibiotics revealed hydrazine as an
active moiety. The main objective of the study is to overcome the
inherited toxicity associated with the free hydrazine. A series of
hydrocarbon bridges was inserted in between the groups, to separate
the two amino groups. Hence, the aminomethylpiperidine-containing
analog 16 was identified as a new promising antibacterial
agent with efficient antibacterial and pharmacokinetic profiles. Briefly,
compound 16 outperformed vancomycin in terms of the antibacterial
spectrum against vancomycin-resistant staphylococcal and enterococcal
strains with minimum inhibitory concentrations (MICs) ranging from
2 to 4 μg/mL, which is a faster bactericidal mode of action,
completely eradicating the high staphylococcal burden within 6–8
h, and it has a unique ability to completely clear intracellular staphylococci.
In addition, the initial pharmacokinetic assessment confirmed the
high metabolic stability of compound 16 (biological half-life
>4 h); it had a good extravascular distribution and maintained
a plasma
concentration higher than the average MIC value for over 12 h. Moreover,
compound 16 significantly reduced MRSA burden in an in vivo MRSA skin infection mouse experiment. These attributes
collectively suggest that compound 16 is a good therapeutic
candidate for invasive staphylococcal and enterococcal infections.
From a mechanistic point of view, compound 16 inhibited
undecaprenyl diphosphate phosphatase (UppP) with an IC50 value of 29 μM.
For the first time, A. baumannii KdpE is shown to be crucial to pneumonia onset, and targeting this system can be a viable approach to treating these fatal infections.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.